Dr. Ruchit Bhatnagar is evaluating a strategic investment in APAC Biotech as the Indian biotechnology company prepares for its next phase of growth in personalised cancer immunotherapy.
The proposed association is expected to focus on more than financial capital alone. The wider objective is to strengthen APAC Biotech’s scientific, manufacturing and clinical capabilities in India while laying the groundwork for a future international expansion, with the UAE being considered as the principal market for a second phase.
APAC Biotech has spent more than a decade developing personalised immunotherapies for cancer. The company’s flagship therapy, APCEDEN®, uses dendritic cells derived from the patient as part of a personalised treatment process. According to APAC, the therapy is designed to help the immune system recognise tumour cells more effectively. The company also states that its development programme has progressed through clinical studies, regulatory processes, hospital partnerships and patent protection in India.
The discussions with Dr. Ruchit Bhatnagar are not new. The parties had explored an investment framework in 2023, and the current process seeks to take those discussions forward in a more structured manner.
The first priority is expected to remain India. APAC already works with healthcare institutions across several major Indian cities, giving the company an existing clinical base from which to expand. Further investment could support additional laboratory capacity, research programmes, specialist teams, patient access and stronger institutional relationships.
For Dr. Ruchit Bhatnagar, the opportunity also fits into a broader healthcare investment strategy. Through RB Investment LLC, he has previously outlined plans for diagnostics, digital healthcare platforms and healthcare partnerships across Gulf markets. His existing initiatives have focused on combining physical healthcare infrastructure with technology and regional expansion.
The longer-term APAC strategy could follow a similar India-to-Gulf approach.
Once the Indian platform has been strengthened, the parties are expected to evaluate a UAE expansion involving patient access, clinical partnerships and potentially specialised biotechnology infrastructure.
The proposed investment remains subject to due diligence, technical and commercial feasibility studies, regulatory review and mutually agreed definitive documentation.
The approach reflects a long-term investment thesis rather than a short-term capital transaction: build a strong scientific and operating platform in India first, then expand that capability into markets where there is a clear clinical and commercial opportunity.
About the Author
